[1]Vaidya A, Mulatero P, Baudrand R, Adler GK.The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis,Pathogenesis,and Treatment[J].Endocr Rev, 2018, 39(6):1057-1088
[2]Koizumi M, Niimura F, Fukagawa M, Matsusaka T.Adipocytes do not significantly contribute to plasma angiotensinogen[J].J Renin Angiotensin Aldosterone Syst, 2016, 17(4):1470320316672348-/
[3]Goodfriend, T.L.,ME. Elliott,and K.J. Catt.Angiotensin receptors and their antagonists[J].N Engl J Med, 1996, 334(25):1649-1654
[4]Dunn, J D.et al.The burden of hyperkalemia in patients with cardiovascular and renal disease[J].Am J Manag Care, 2015, 21(15 Suppl):s307-15
[5]Korgaonkar, S, et al.Serum Potassium and Outcomes in CKD: Insights from the RRI-CKD Cohort Study[J].Clinical Journal of the American Society of Nephrology, 2010, 5(5):762-769
[6]Montford, J R.and SLinas.How Dangerous Is Hyperkalemia?[J].Journal of the American Society of Nephrology, 2017, 28(11):3155-3165
[7]Knoll, G A.Renin-Angiotensin System Blockade and the Risk of Hyperkalemia in Chronic Hemodialysis Patients[J].The American Journal Of Medicine, 2002, 112(/):110-114
[8]Han, S.W., et al..No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients[J]. Nephrol Dial Transplant, 2007, 22(4):1150-1155
[9]Movilli, E, et al..Use of Renin-Angiotensin System Blockers Increases Serum Potassium in Anuric Hemodialysis Patients[J].American Journal of Nephrology, 2018, 48(2):79-86
[10]Yusuf, S, et al..Telmisartan, ramipril, or both in patients at high risk for vascular events[J]. N Engl J Med, 2008, 385(15):1547-1559
[11]Chang, A R., et al..Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System[J]. Hypertension, 2016, 67(6):1181-1188
[12]Fishbane, S , et al..Consensus-Based Recommendations for the Management of Hyperkalemia in the Hemodialysis Setting. [J].J Ren Nutr, 2021, S1051-2276(21):161-168
[13]Lopes, A A., et al..Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS.[J].Nephrol Dial Transplant, 2009, 24(9):2809-2816
[14]Lewis, E J., et al..The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. [J].N Engl J Med, 1993, 329(20):1456-1462
[15]Molnar, M Z., et al.Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease.[J].J Am Coll Cardiol, 2014, 63(7):650-658
[16]Wu, C K., et al..Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis. [J].Medicine (Baltimore), 2015, 94(3):e424-/
[17]Kido, R, et al..Interactive Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers or Their Combination on Survival of Hemodialysis Patients[J].American Journal of Nephrology, 2017, 46(6):439-447
[18]Karaboyas, A , et al..DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients[J].Kidney Int, 2018, 94(3):589-598
[19]Ramos, C I., et al..Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease? [J].Nephrol Dial Transplant, 2020, 36(11):2049-2057
[20]Zhang, Q , et al..Hyperkalemia of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in hemodialysis: a meta-analysis. [J].J Huazhong Univ Sci Technolog Med Sci, 2012, 32(5):785-792
[21]Clase, C M., et al..Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2020, 97(1):42-61
[22]Palmer, B F., et al..Clinical Management of Hyperkalemia[J]. Mayo Clin Proc, 2021, 96(3):744-762
[23]中华医学会肾脏病学分会专家组.中国慢性肾脏病患者血钾管理实践专家共识[J].中华肾脏病杂志, 2020, /(10):781-792
[24]Annette Alfonz，lexander Harrison， Richard Baines，Ann Chu，Simon Mann，Murdoch MacRury.Renal Association Clinical Practice Guidelines – Treatment of Acute Hyperkalaemia in Adults[J].Circ Cardiovasc Qual Outcomes, 2020, 13(9):e006415-/
[25]Kim, H J. and S.W. Han,.Therapeutic approach to hyperkalemia[J]. Nephron, 2002, 92(Suppl 1):33-40
[26]Long, B , J.R. Warix, and A. Koyfman.Controversies in Management of Hyperkalemia[J].J Emerg Med, 2018, 55(2):192-205
[27]Brunelli, S M., et al..Serum Potassium and Short-term Clinical Outcomes Among Hemodialysis Patients: Impact of the Long Interdialytic Interval[J].Am J Kidney Dis, 2017, 70(1):21-29
[28]Bianchi, S, et al..Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology[J].Journal of Nephrology, 2019, 32(4):499-516
[29]Pun, P H. and J.P. Middleton.Dialysate Potassium, Dialysate Magnesium, and Hemodialysis Risk[J].J Am Soc Nephrol, 2017, 28(12):3441-3451
[30]Ferrey, A , et al.. Dialysate Potassium and Mortality in a Prospective Hemodialysis Cohort[J].Am J Nephrol, 2018, 47(6):415-423
[31]Foley, R N., et al..Long interdialytic interval and mortality among patients receiving hemodialysis.[J].N Engl J Med, 2011, 365(12):1099-1107
[32]D' Alessandro, C , et al..Prevalence and correlates of hyperkalemia in a renal nutrition clinic.[J]. Intern Emerg Med, 2021, 16(1):125-132
[33]Cupisti, A , et al..Dietary Approach to Recurrent or Chronic Hyperkalaemia in Patients with Decreased Kidney Function. [J].Nutrients, 2018, 10(3):261-/
[34]鲍云非, 王兰, and 左力, 鲍云非, 王兰, 左力.慢性肾脏病患者高钾血症的易发因素及护理对策[J].中华现代护理杂志, 2011, /(34):4232-4234
[35]Ahmed, A, T. Jorna, and S. Bhandari.Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?[J].Nephron, 2016, 133(3):147-158
[36]Qiao, Y , et al..Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate[J].JAMA Intern Med, 2020, 1880(5):718-726
[37]Linde, C , et al..Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. [J].J Am Heart Assoc, 2019, 8(22):e012655-/
[38]Bansal, S and P.E. Pergola.Current Management of Hyperkalemia in Patients on Dialysis[J].Kidney Int Rep, 2020, 5(6):779-789
[39]Hunt, T V., et al..Single-dose sodium polystyrene sulfonate for hyperkalemia in chronic kidney disease or end-stage renal disease.[J]. Clin Kidney J, 2019, 12(3):408-413
[40]Lepage, L , et al..Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD. [J].Clin J Am Soc Nephrol, 2015, 10(12):2136-2142
[41]Noel, J A., et al..Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age. [J].JAMA Intern Med, 2019, 179(8):1025-1033
[42]Harel, Z, et al..Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review[J].Am J Med, 2013, 126(3):264.e9-24
[43]Seliger, S L..Hyperkalemia in patients with chronic renal failure[J]. Nephrology Dialysis Transplantation, 2019, 34(Supplement_3):iii12-iii18
[44]Palmer, B F. .Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis. [J].Mayo Clin Proc , 2020, 95(2):339-354
[45]Kosiborod, M, et al..Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial [J].Jama, 2014, 312(21):2223-2233
[46]Pitt, B, et al..Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. [J].Eur Heart J, 2011, 32(7):820-828
[47]Spinowitz, B S., et al..Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.[J].Clin J Am Soc Nephrol,, 2019, 14(6):798-809
[48]Fishbane, S , et al..A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia [J].J Am Soc Nephrol, 2019, 30(9):1723-1733
[49]Yoo, K D., et al..Effect of Renin-Angiotensin-Aldosterone System Blockade on Outcomes in Patients With ESRD: A Prospective Cohort Study in Korea[J].Kidney Int Rep, 2018, 3(6):1385-1393
